Precision molecular imaging serves as an essential foundation of radionuclide drug conjugate (RDC) development, providing indispensable data on pharmacokinetics and therapeutic efficacy. This platform delivers high-resolution, quantitative imaging solutions tailored to specific tracer characteristics, spanning from initial radiolabeling to comprehensive biodistribution analysis. By integrating state-of-the-art instrumentation with expert radiopharmaceutical insights, Alfa Cytology's customized, one-stop services accelerate the identification of promising lead candidates while ensuring rigorous preclinical validation.
Preclinical imaging of RDCs leverages non-invasive modalities to visualize and quantify the spatiotemporal distribution of radiolabeled compounds within living subjects. This phase is critical for evaluating target engagement, determining the optimal therapeutic window, and assessing off-target accumulation in vital organs. High-sensitivity detection systems allow for the real-time monitoring of biological processes, providing a bridge between in vitro binding affinity and in vivo biological performance. Modalities commonly applied include positron emission tomography (PET), single-photon emission computed tomography (SPECT), and optical imaging, often fused with computed tomography (CT) for anatomical localization.
Fig.1 Quality data required for radiopharmaceutical translation. (Bolcaen, J., et al., 2021)
Preclinical imaging of RDCs requires modality selection based on radionuclide decay characteristics (positron vs. single-photon emitter), temporal resolution, and need for anatomical co-localization. PET offers the highest sensitivity and true quantification for positron-emitting isotopes, while SPECT enables multi-isotope discrimination and compatibility with therapeutic radionuclides. Optical imaging serves as a complementary, non-radioactive tool for early validation, and fusion with CT or MRI provides attenuation correction and precise anatomical context.
PET/CT Imaging
Detects coincident gamma photons from positron annihilation, providing high sensitivity and absolute quantification. Well-suited for fast kinetics and isotopes with half-lives from minutes (⁶⁸Ga) to days (⁸⁹Zr).
SPECT/CT Imaging
Directly detects gamma rays from single-photon emitters such as ¹¹¹In, ¹⁷⁷Lu, and ²²³Ra. Capable of sequential multi-isotope imaging, essential for therapeutic RDCs with longer half-lives.
Optical Imaging (BLI/FLI)
Bioluminescence and fluorescence imaging track cells or dye-labeled probes without radionuclides. Useful for tumor engraftment validation and longitudinal relative comparisons in superficial models.
Multi-modality Fusion
Coregisters PET/SPECT with CT or MRI for attenuation correction and anatomical delineation. MRI fusion offers superior soft tissue contrast for brain or abdominal RDC studies.
Leveraging specialized radiochemistry expertise, validated animal models, and state-of-the-art multimodality imaging systems, Alfa Cytology provides a complete portfolio of quantitative imaging services. Expert physicists and biologists collaborate to provide rigorous dosimetry calculations and kinetic modeling, ensuring that every study protocol is optimized for the specific physical properties of the selected radionuclide and the biological requirements of the target model.
Preclinical imaging support is available for a broad panel of positron-emitting, single-photon-emitting, and therapeutic radionuclides used in RDC development. Each isotope requires tailored acquisition parameters (energy windows, coincidence timing, collimation) and calibration protocols to ensure accurate quantification.
| Isotopes | Imaging Type | Description |
|---|---|---|
| ¹⁸F | PET/CT | High positron branching fraction; gold standard for rapid kinetics and small-molecule RDCs. |
| ⁸⁹Zr | PET/CT | Long half-life; standard for mAb-based RDCs requiring delayed imaging (days post-injection). |
| ⁹⁹ᵐTc | SPECT/CT | Most accessible SPECT isotope; excellent for chelate stability and rapid biodistribution studies. |
| ⁶⁴Cu | PET/CT | Versatile PET isotope for both small molecules and antibodies; Auger electron therapy potential. |
| ¹²³I | SPECT/CT | Gamma energy ideal for SPECT; shorter half-life than ¹²⁵I, suitable for same-day imaging. |
| ¹³¹I | SPECT/CT | Therapeutic beta/gamma emitter; direct imaging of iodine-labeled RDCs (e.g., for thyroid or neuroendocrine tumors). |
| ¹⁷⁷Lu | SPECT/CT | Therapeutic beta emitter with multiple gamma photons; enables direct imaging of therapeutic RDC distribution. |
| ¹¹¹In | SPECT/CT | Long-lived surrogate for therapeutic lanthanides (e.g., ¹⁷⁷Lu); standard for dosimetry. |
| ⁴⁷Sc | SPECT/CT | Beta/gamma emitter (159 keV); promising therapeutic analog to ¹⁷⁷Lu with SPECT capability. |
| ⁶⁸Ga | PET/CT | Generator-produced; ideal for peptide-based RDCs without an on-site cyclotron. |
| ¹⁸⁸Re | SPECT/CT | Beta/gamma emitter; similar to ⁹⁹ᵐTc chemistry but therapeutic; 155 keV gamma suitable for SPECT. |
| ¹⁵³Sm | SPECT/CT | Beta/gamma emitter; used for bone-targeting RDCs; SPECT imaging feasible via its 103 keV gamma. |
| ¹⁶¹Tb | SPECT/CT | Emerging therapeutic isotope with gamma emissions suitable for SPECT; analogous to ¹⁷⁷Lu. |
A full range of in vivo imaging acquisition and post-acquisition quantitative analysis services is available to support RDC characterization from early target validation to dosimetry. Each service modality and analysis workflow are customized based on the isotope, tracer kinetics, and specific biological question being addressed.
A full panel of in vivo imaging modalities is available to capture RDC distribution, target engagement, and longitudinal response. Each modality is supported by appropriate animal handling, anesthesia, isotope calibration, and acquisition protocols optimized for radionuclide-based or optical probes.
High-sensitivity, fully quantitative imaging for positron-emitting isotopes (e.g., ⁸⁹Zr, ⁶⁴Cu, ¹⁸F, ⁶⁸Ga). Dynamic and static scans are performed with CT-based attenuation and anatomical localization. Typical outputs include %ID/g, SUVmean/max, and time-activity curves. Applications range from tumor targeting kinetics to normal organ dosimetry.
Designed for single-photon emitters (e.g., ¹¹¹In, ⁹⁹ᵐTc, ¹⁷⁷Lu, ²²³Ra). Multi-energy window acquisition enables sequential imaging of two isotopes (or simultaneous with appropriate crosstalk correction). Data are reconstructed with iterative algorithms, scatter correction, and CT co-registration. SPECT/CT is particularly valuable for therapeutic RDCs with longer physical half-lives.
Includes both bioluminescence (BLI) for cell tracking and fluorescence (FLI) for dye-labeled RDCs or co-administered probes. Although not radionuclide-based, optical imaging serves as a cost-effective, high-throughput complement for early validation or longitudinal studies in non-radioactive formats. Co-registration with PET/SPECT is available for multi-modal correlation.
Provided as an optional service for anatomical reference, soft tissue contrast, or specific functional readouts (e.g., perfusion, necrosis). MRI does not directly image radionuclides but can be fused with PET or SPECT data to improve region-of-interest delineation in orthotopic or brain tumor models. Typically reserved for studies where CT contrast is insufficient.
Raw imaging data are transformed into biologically and statistically interpretable metrics through a standardized post-processing pipeline. All analysis services are delivered with full documentation of algorithms, software tools, and quality assurance steps.
ROI/VOI Quantitative Analysis
Regions of interest (2D) or volumes of interest (3D) are manually drawn, semi-automatically segmented, or atlas-based mapped onto PET/SPECT/CT images. Activity concentrations (%ID/g, SUV, kBq/cc) and tumor-to-background ratios are calculated per organ and time point. Predefined segmentation protocols minimize inter-operator and inter-session variability.
Time-Activity Curve (TAC) Analysis
Serial imaging data (dynamic or multi–time point static) are used to generate TACs for each organ, tumor, or blood pool. Non-linear least squares fitting or compartmental modeling extracts parameters such as peak uptake, washout half-life, area under the curve (AUC), and clearance rate. TACs are essential for dosimetry and PK/PD bridging.
Multi-modal Image Co-registration
PET/CT, SPECT/CT, optical, and MRI datasets are co-registered using mutual information or landmark-based algorithms. Rigid and deformable registration options are available depending on anatomical deformation. Outputs include fused images for visual overlay and aligned volumes for combined ROI analysis across modalities.
Dynamic Pharmacokinetic Modeling
Plasma input functions (derived from image-derived blood pool or arterial sampling) and tissue TACs are fitted to standard PK models: one-/two-tissue compartment models, irreversible trapping, or reference tissue models (e.g., simplified reference tissue model for brain RDCs). Macroscopic parameters are reported for the mechanistic understanding of RDC targeting.
Alfa Cytology provides a complete preclinical imaging solution for RDCs, covering multi-isotope PET/SPECT/CT, tailored workflows, and integrated validation, to advance radiopharmaceutical candidates with confidence. Every imaging study is designed to yield quantitative, reproducible, and biologically meaningful data that de-risk downstream development. For detailed technical inquiries or to discuss a customized project plan, please contact the specialist team today to initiate a consultation.
References
For research use only. Not intended for any clinical use.
Alfa Cytology, a provider of RDC preclinical services, specializes in RDC design, conjugation, and analysis. Supported by a rich library of radionuclides, chelators, and linkers, we excel in targeting molecule design. We offer customized RDC services tailored to diverse requirements-your demand is our mission.
Copyright © 2026 Alfa Cytology. All rights reserved.